● PM answer
Do not confuse a low multiple with a completed underwrite.
At $22.43, WAY trades at roughly 10.8× 2026E adjusted EBITDA, 13.7× adjusted EPS, and a 7.7% consensus FCF yield on the diluted share count implied by guidance. That is appealing for a platform growing near 10% organically with 43% adjusted EBITDA margins. But the $1.26bn Iodine acquisition added debt, 16.6m shares, and nearly $1.0bn of goodwill without standalone revenue, retention, synergy, or cash-return disclosure. The correct long-only posture is a watchlist initiation, not a positive rating: demand operating proof at the next print and August Investor Day, then consider a 50–75bp starter if organic provider growth holds at ≥10%, NRR stays around 110%, Iodine economics become auditable, and leverage is visibly declining. S1 S2 S9
No formal rating or price target is assigned. The $25–30 valuation reference is a scenario-based decision aid, not a recommendation.
Last close
$22.43
July 10 close; thin pre-market trading excluded.
2026E FCF yield
7.7%
Consensus FCF / ~199.4m forward diluted shares.
Net leverage
2.7×
Company-defined; $1.319bn net debt at March 31.
Valuation reference
$25–30
DCF and 2027E adjusted-EPS cross-check; not a target.
Debate 01
Is the core engine really low double digit?
FactQ1 organic growth was approximately 11%, including about 14% organic subscription growth; volume revenue grew 7.3%. JudgmentThe durability test is the 2026–27 renewal of clients won after the Change Healthcare cyberattack. S2 S4
Debate 02
Does Iodine earn its cost of capital?
FactWAY paid $1.26bn, financed with cash, debt, and 16.64m shares. JudgmentThe strategic fit is plausible, but management has not disclosed enough standalone financials to prove after-financing returns. S1 S15
Debate 03
Is AI a moat or a feature set?
Company claimAbout 40% of Q1 bookings involved AI-powered capabilities. JudgmentBookings labels are not differentiation; renewal lift, verified labor removal, pricing, and cash conversion are.
Capital return & funding gate
Iodine is the gate; the buyback is a capital-allocation test.
Management authorized a discretionary $200m repurchase in May. At current prices that could retire roughly 4.5% of forward diluted shares, but meaningful execution would compete with deleveraging. Until Iodine's return bridge is visible, debt reduction should have priority.
Gross debt
$1.478bn
Mostly first-lien term debt; material maturity concentration in 2029.
Net debt
$1.319bn
Cash plus investments netted; restricted cash excluded.
Iodine price
$1.260bn
~$639m cash plus ~$621m equity; standalone return bridge missing.
Funding verdict
Unproven
No disclosed Iodine FCF, ROIC, retention, or realized synergy schedule.
Acquisition caseAt announcement, management described Iodine as approximately 99% subscription, with 75% gross margin and 40% adjusted EBITDA margin, targeted at least $15m of run-rate cost synergies, and characterized the price as a high-teens multiple of synergized 2025E EBITDA. It expected neutral non-GAAP EPS impact in 2026 and modest accretion in 2027. Those forward claims do not replace a disclosed after-financing return bridge. S15
Business quality
Software economics riding healthcare transaction flows
WAY is better understood as a provider-facing healthcare transaction network and workflow-software vendor than as a labor-heavy RCM outsourcer. Its platform covers eligibility, prior authorization, claims, denials, clinical documentation, and patient payments across more than 500 integrations. S1
Clients
30k+
More than one million distinct providers.
2025 transactions
7.5bn+
Company-reported platform activity.
Gross claims
$2.4tn
Company-reported 2025 scale.
Top-10 clients
10.8%
Low customer concentration versus RCM outsourcers.
Why the model is attractive
- FactMore than 99% of revenue is subscription or predictable volume-based; roughly 98% of 2025 revenue came from clients under contract at the start of the year.
- FactTypical initial contracts run two to three years, generally auto-renew annually, and often include price escalators.
- FactProvider solutions are approximately 75% of revenue and carry only about 6–7% direct third-party cost.
- FactWAY serves hospitals and health systems as well as ambulatory and alternate-care providers, limiting single-end-market dependence.
What lowers the quality score
- FactPatient payments are about 25% of revenue and face roughly 60% direct third-party cost, utilization, coverage, card-fee, and print-to-digital exposure.
- FactClients can terminate with limited notice after the initial term; backlog, ARR, bookings dollars, CAC/payback, and gross retention are not disclosed.
- FactGoodwill plus intangibles exceed total equity; tangible equity is approximately negative $1.34bn.
- JudgmentAdjusted EBITDA excludes meaningful D&A, stock compensation, and acquisition costs, so cash conversion and per-share dilution matter more than headline margins.
Revenue mix is shifting toward subscription
Percent of total revenue; recurring does not mean equally high margin
Revenue architecture
| Period | Subscription | Volume | Other |
|---|
| FY2025 | $558.4m / 50.8% | $534.8m / 48.6% | $6.1m / 0.6% |
| Q1 2026 | $172.2m / 54.9% | $139.5m / 44.4% | $2.2m / 0.7% |
FactSubscription grew 37.7% reported and approximately 14% organically in Q1. Volume grew 7.3%. Iodine is predominantly subscription revenue, so the mix shift is not purely organic.
Competitive frame
| Competitive set | Primary strength | Implication for WAY |
|---|
| Optum / Change, Availity | Payer-provider connectivity and clearinghouse scale. | Most direct network threat; WAY must sustain service, resilience, and workflow differentiation after Change-related wins renew. |
| Epic, Oracle Health, athenahealth | EHR-native workflow, installed base, and bundling. | Clearest disintermediation risk as authorization, billing, and AI features move inside core systems. |
| Experian Health | Patient access, identity, credit data, claims, and collections. | Credible modular competitor, particularly in patient access and payments. |
| R1, Ensemble | Deep labor/process ownership under long operating contracts. | Often coopetitors, not clean comps; WAY has better software economics, but less control over client outcomes and wallet. |
Thesis & variant perception
The edge must come from proof, not from the word “AI”
The investable variant is that WAY's provider-software economics and durable Change-related share gains are being misread as low-quality RCM or acquisition growth. The bear response is equally credible: normalization, EHR bundling, and a high-priced Iodine deal can absorb the apparent valuation discount.
Variant candidate
Software quality is underappreciated
Provider solutions have high incremental economics, broad client diversification, and cross-sell opportunity across a fragmented provider base.
Prove it: ≥10% organic provider growth, stable 43% adjusted EBITDA margin, and strong levered FCF after SBC.
Variant candidate
Change wins may be durable share transfer
More than 30,000 providers adopted WAY after the 2024 competitor outage, generally on initial two-to-three-year contracts.
Prove it: Stable NRR and gross retention through the 2026–27 renewal window, excluding price and acquired revenue.
Variant candidate
Iodine adds clinical-financial depth
Clinical documentation and pre-bill intelligence can widen the moat and attach more revenue to hospital workflows.
Prove it: Standalone Iodine growth, retention, cross-sell, realized cost synergy, and an ROIC/FCF bridge.
Question
Evidence today
Required proof
Status
Core organic durability
Q1 organic growth ~11%; NRR 110.5%
2026–27 Change cohort renewals; organic provider mix
Open
Operating leverage
Q1 adjusted EBITDA margin 43.1%
Levered FCF growth after SBC and interest
Supported
Iodine integration
Management says ahead of plan; no audited bridge
Revenue, EBITDA, retention, synergy, and ROIC
Unproven
AI differentiation
~40% of Q1 bookings labelled AI-powered
Paid SKU attach, renewal lift, accuracy, labor removal
Promising / soft
Balance-sheet flexibility
2.7× net leverage; 2029 maturity concentration
Net leverage <2.5× before material buybacks
Constrained
Secular support
FactCMS projects U.S. national health expenditures to grow 5.4% annually in 2025–34, faster than GDP. Claims, reimbursement complexity, and patient-payment flows remain structurally large.
FactThe CAQH Index estimates a roughly $20bn remaining annual savings opportunity from transaction automation. Prior-authorization API rules create implementation demand.
The double edge
JudgmentStandardization can reduce manual friction but also commoditize basic connectivity and lower switching costs. Coverage losses can suppress claims/payment volume while increasing demand for eligibility and discovery tools. Security scale raises entry barriers and makes a breach more damaging.
Earnings & model
Consensus expects cash growth without much margin expansion
The forecast is plausible, but its composition matters more than the headline. Provider solutions and Iodine subscription growth need to offset slower patient payments, while share dilution and interest limit the benefit to owners.
Revenue, adjusted EBITDA, and free cash flow trajectory
$m; 2026–28 are Fiscal.ai consensus estimates accessed July 13, 2026
| $m except per share | 2023A | 2024A | 2025A | 2026E | 2027E | 2028E |
|---|
| Revenue | 791.0 | 943.5 | 1,099.3 | 1,284.7 | 1,422.1 | 1,592.3 |
| Growth | — | 19.3% | 16.5% | 16.9% | 10.7% | 12.0% |
| Adjusted EBITDA | — | 383.5 | 462.1 | 537.9 | 601.1 | 690.0 |
| Adjusted EBITDA margin | — | 40.6% | 42.0% | 41.9% | 42.3% | 43.3% |
| Free cash flow | — | — | 283.2 | 346.3 | 395.5 | 437.1 |
| Adjusted EPS | — | — | 1.42 | 1.64 | 1.85 | 2.16 |
Q1 cash reality
FactCFO was $84.9m and capitalized software/capex was $15.3m. Conventional after-interest FCF was therefore about $69.6m.
The company's $90.3m “unlevered FCF” adds back $20.7m of cash interest; it is not equity cash flow.
Dilution reality
DerivedFY2026 guidance implies roughly 199.4m diluted weighted-average shares, versus 191.8m basic and 195.2m in Q1.
Forward valuation uses the guidance-implied count; a full repurchase is not assumed.
Rate reality
FactAbout $550m of debt is hedged through March 2027; the balance is largely floating.
DerivedA 100bp move on roughly $828m unhedged debt is about $8.3m pretax annually.
Latest-quarter read-through
| KPI | Q1 2026 | Read-through |
|---|
| Revenue / growth | $313.9m / +22.4% | Approximately 11% organic; acquisition contribution is material but core growth remains respectable. |
| Subscription / growth | $172.2m / +37.7% | Approximately 14% organic; Iodine elevates reported growth and quality mix. |
| Volume / growth | $139.5m / +7.3% | Slower patient-payment activity and print-to-digital conversion weigh on headline revenue. |
| NRR | 110.5% | Down from 113.5%; includes price, utilization, cross-sell and Change tailwinds, but excludes Iodine until the ninth quarter. |
| Clients >$100k LTM | 1,433 / +15% | Organic growth was ~12%; about half the sequential increase came from Iodine. |
| Adjusted EBITDA margin | 43.1% | Strong operating performance; still reconcile to interest, SBC, acquisition costs, and dilution. |
Valuation & expectations
The stock prices skepticism; the Street still prices success
At the July 10 close, WAY offers an attractive prospective cash yield. Yet the mean sell-side price target remains $33.57, so “cheap versus consensus” is not a variant. The edge requires better evidence on organic durability and Iodine returns than the market currently has.
2026E EV / revenue
4.5×
~$5.81bn EV on forward diluted equity.
2026E EV / adj. EBITDA
10.8×
Consensus adjusted EBITDA $537.9m.
2026E adj. P/E
13.7×
Consensus adjusted EPS $1.64.
2026E P / FCF
12.9×
Forward-diluted market cap / $346.3m FCF.
Peer context — discount is real, comparability is not
| Ticker | NTM EV / sales | NTM EV / EBITDA | NTM P/E | NTM P / FCF | 2-year revenue CAGR |
|---|
| WAY | 4.28× | 10.25× | 13.36× | 10.52× | 13.7% |
| ACIW | 3.33× | 11.82× | 15.83× | 17.24× | 7.8% |
| HQY | 5.98× | 13.31× | 19.40× | 17.93× | 7.8% |
| DOCS | 4.86× | 9.90× | 15.24× | 14.33× | 5.1% |
| VEEV | 6.37× | 14.15× | 20.73× | 19.35× | 13.0% |
| Peer median | 5.42× | 12.57× | 17.62× | 17.59× | 7.8% |
Provider dataFiscal.ai NTM snapshots accessed July 13. WAY trades at roughly 21% / 18% / 24% discounts to the peer medians on EV/sales, EV/adjusted EBITDA, and adjusted P/E despite faster median growth. Net leverage, acquisition risk, non-GAAP adjustments, and sponsor overhang justify some discount; DOCS and VEEV are net cash. Snapshot multiples use provider quote timestamps and are for relative context, while report valuation uses the frozen July 10 close. S9
Equity FCF DCF sensitivity
Value per share; 2026–28 consensus, 2029–30 assumptions of +9% / +8%, ~199.4m diluted shares
DCF sensitivity table
| Discount rate \ terminal growth | 2.5% | 3.0% | 3.5% |
|---|
| 9.5% | $32.21 | $34.18 | $36.48 |
| 10.5% | $28.06 | $29.50 | $31.15 |
| 11.5% | $24.83 | $25.92 | $27.15 |
Assumption2029–30 FCF grows 9% and 8%; no acquisition spending or share repurchase is assumed. The DCF uses consensus FCF as equity cash flow. If provider-defined FCF differs materially from after-interest cash generation, these values would be too high.
Cross-check15× 2027E adjusted EPS of $1.85 yields $27.75. Together these methods support a provisional $25–30 reference band.
One-year scenario values
Research scenarios, not formal price targets; dotted line is $22.43 last close
Scenario framework
| Case | Value | Probability | Mechanism |
|---|
| Bear | $18 | 25% | Organic growth slips to mid single digit, NRR weakens on Change renewals, and Iodine does not earn its financing cost. |
| Base | $29 | 55% | About 10% core growth, stable low-40s adjusted EBITDA margin, and gradual deleveraging; Iodine proof improves. |
| Bull | $36 | 20% | Provider software and Iodine cross-sell sustain low-teens growth, AI attach is paid and durable, leverage falls quickly. |
| Probability-weighted | $27.65 | 100% | Approximately 23% above the frozen close, before timing and execution risk. |
PM judgmentThe expected-return math is adequate for a starter, but the capital-return gate is not. Evidence, not another turn of multiple expansion, is the gating item.
Positioning and technical context
| Signal | Observation | Portfolio implication |
|---|
| Performance | Down roughly 40% over one year and 32% YTD through July 10; 52-week range $17.26–41.47. | Expectations have reset, but falling price alone does not identify the trough in organic estimates. |
| Sponsor ownership | EQT, CPPIB, Bain, and Advent owned approximately 35.6% as of April 10. | Registration rights and secondary-sale history create block overhang and governance considerations. |
| Institutional ownership | Approximately 83% on a secondary market-data basis. | Institutional sponsorship is broad; estimate revisions can move the stock quickly. |
| Short interest | 12.93m shares at June 30, about 6.7% of basic shares and 4.0 days to cover. | Meaningful skepticism, but not a structurally crowded short; float-based percentages vary by vendor. |
| Liquidity | Recent 20-day average volume near 3.0m shares. | Adequate liquidity for a small/mid-cap starter; sponsor blocks can change the float. |
Catalysts & path to action
The next two disclosures should decide the initiation
Late July 2026 · soft date
Q2 earnings
Third-party calendars estimate July 29, but WAY had not confirmed the date on its IR page at the cut-off. Watch sequential revenue cadence, provider versus patient-payment organic growth, NRR, implementation backlog conversion, and leverage.
August 25, 2026 · confirmed
Investor Day
The highest-value event for stable AI definitions, Iodine revenue/synergy/cross-sell disclosure, normalized NRR, autonomous-RCM roadmap, and customer evidence.
2026–27
Change cohort renewal window
Clients won after the 2024 cyberattack signed initial two-to-three-year terms. Renewal economics will determine whether the share shift is durable.
Upgrade triggers: move from watchlist to starter
- Organic provider-solution growth at or above 10%, with the patient-payment drag quantified.
- NRR around 110% or better and a clear bridge for Change-related renewals, price, volume, and cross-sell.
- Iodine revenue, EBITDA, retention, realized synergy, and cross-sell disclosure sufficient to estimate ROIC.
- Net leverage trending below 2.5× before material use of the $200m repurchase authorization.
- AI bookings convert into paid revenue, renewal uplift, or validated labor/denial improvement under stable definitions.
Risks & falsifiers
Observable ways the thesis can fail
Retention breaks
NRR falls below the historical 108–110% zone, or Change-acquired clients churn/downsize at renewal.
Iodine disappoints
Weak cross-sell, delayed synergies, client losses, impairment, or dilution beyond 2026 proves the deal did not cover its financing cost.
Bundling wins
Epic, Oracle, Optum, or Availity captures major consolidations by bundling connectivity and AI inside core workflows.
Patient payments weaken
Coverage, utilization, ability-to-pay, card fees, or print-to-digital changes reduce volume and revenue faster than cost savings offset.
AI remains marketing
AI-labelled bookings fail to convert into paid revenue, retention, margin, or independently measurable labor reduction.
Security / compliance event
A breach, PHI-permission failure, inaccurate model, or false-claims issue damages provider trust and raises regulatory cost.
Key evidence gaps
| Missing disclosure | Why it matters | Priority |
|---|
| Iodine standalone revenue, EBITDA, FCF, retention, cross-sell, and realized synergies | Required to test the largest capital-allocation decision and after-financing return. | Critical |
| Organic revenue by provider and patient-payment solution | Separates high-quality software growth from lower-margin transaction and acquisition effects. | Critical |
| Gross retention, churn, ARR, bookings dollars, backlog, and CAC/payback | NRR alone mixes price, volume, and cross-sell and excludes acquisitions for eight quarters. | High |
| Stable AI revenue/bookings definition and verified customer outcomes | Necessary to distinguish a monetizable product moat from embedded feature marketing. | High |
| Provider- versus patient-payment segment margins | Mix can improve revenue quality even when consolidated headline growth slows. | Medium |
Evidence control
Sources, assumptions, and conflicts
Primary filings anchor the facts. Company performance claims remain labelled; consensus and derived figures are separated from reported results. Market data is frozen to the July 10 regular-session close.
- Waystar 2025 Form 10-KSEC · Tier 1 · filed Feb. 17, 2026
Business, KPIs, financials, Iodine, risks
- Waystar Q1 2026 Form 10-QSEC · Tier 1 · filed Apr. 29, 2026
Quarter, balance sheet, debt, cash flow
- Q1 2026 earnings releaseCompany IR · Tier 1
Guidance and reconciliations
- Q1 2026 investor presentationCompany IR · Tier 1 company material
Organic growth and KPI bridges
- Q1 earnings eventCompany IR · official audio
Bookings, cadence, AI and patient-payment commentary
- 2026 proxy statementSEC · Tier 1 · filed Apr. 17, 2026
Ownership and governance
- $200m repurchase authorizationCompany IR · May 19, 2026
Capital allocation
- Investor Day announcement / eventsCompany IR · checked July 13, 2026
Confirmed event schedule
- Fiscal.ai via local wrapperStandardized provider data · accessed July 13, 2026
python3 fiscal_ai/fiscal_data.py … NasdaqGS-WAY for overview and annual revenue, EPS, EBITDA, FCF, and price-target estimates.
- Stock AnalysisSecondary market data · checked July 13, 2026
Regular-session price, volume, float, valuation and ownership statistics
- Nasdaq short interestExchange market data · June 30, 2026 settlement
Short interest and days to cover
- CMS national health expenditure projectionsU.S. government · updated June 24, 2026
Healthcare expenditure growth
- 2024 CAQH IndexIndustry primary research
Administrative-transaction automation opportunity
- CMS prior-authorization final-rule fact sheetU.S. government
FHIR APIs, denial reasons and compliance timing
- Waystar Iodine acquisition presentationCompany IR · July 23, 2025
Deal rationale, margin profile and synergy target
- CMS Change Healthcare responseU.S. government · March 9, 2024
Independent context on industry disruption
Important conflicts and conventions
- NRR is 110.5% in the 10-Q and rounded to 111% in earnings materials; this report uses the exact filing value.
- Iodine is included in the >$100k customer count but will not enter NRR until its ninth quarter; the KPIs have different acquisition treatment.
- Fiscal.ai's 2025 EPS of $1.42 is adjusted/normalized, not GAAP EPS. Forecast P/E therefore uses adjusted EPS.
- The enterprise-value bridge uses the July 10 close, ~199.4m guidance-implied diluted shares, $1.319bn net debt, and $16.5m leases. Vendor EV figures differ because share count and price timestamps differ.
- No company-confirmed Q2 earnings date was found at the cut-off; the late-July date is explicitly soft.
Method limits
- The DCF uses provider consensus FCF because detailed FCFE components are not all disclosed. It assumes that figure represents after-interest equity cash generation.
- No clean public comparable exists. PHR, DOCS, HCAT and PRVA differ materially in growth, balance sheet, margins, and business mix, so comps are a context check rather than the primary valuation.
- AI outcome metrics, win rates, platform transactions, and gross claims are company claims without independent audit.
- Index membership was not independently verified and is not used in the positioning conclusion.
Research status and disclaimer. This is a preliminary, evidence-controlled initiation underwrite for research discussion. It is not investment advice, a solicitation, or a formal rating. Financial estimates and market data can change; consensus may use non-GAAP definitions that are not fully comparable to reported results. The recommended next handoff is an event-driven model update after Q2 results and the August 25 Investor Day, with special focus on Iodine standalone economics, organic provider growth, NRR composition, dilution, and net leverage.